Cellgen Diagnostics is a privately held molecular diagnostics company developing its proprietary EVAP (patent pending) technology to deliver intelligent quantitative and actionable results to clinicians. Current tissue based molecular test methodologies limit personalized medicine to patients with actionable DNA mutations or aberrations, which only represents approximately 30% of the population. Moreover, it may take up to 21 days for physicians to receive test results. Cellgen is leveraging the value of mRNA based diagnostic to provide treatment options that are not only directed by the biology of each individual patient but would leverage the power of computational science and bioinformatics to accelerate decision making in 2 hours.
Blood based diagnostics are aggressively addressing the barriers of adoption and may help to revolutionize disease research, patient treatment, and survivor care. Cellgen’s non-amplified, bio-fluid based therapeutic guidance platform will incorporate machine learning to deliver intelligent quantitative and actionable results to clinicians in 2 hours. Running on Cellgen’s proprietary platform, each disposable assay will yield inclusion / exclusion data while also leveraging proprietary machine learning algorithms to intelligently monitor and predict therapeutic response. Cellgen is poised to take advantage of the projected multibillion-dollar market growth in the field of personalized medicine by partnering with clinicians and payers to develop predictive tests that would enhance patient outcomes, avoid trial